Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study
Authors:
Open Access
- 29 November 2022
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (8) , 5397-5404
Abstract
Purpose: A potential method for focal therapy in locally advanced prostate cancer is focal brachytherapy (F-BT). The purpose of this research was to evaluate midterm F-BT oncologic, functional, and toxicological results in men who had therapy for prostate cancer. Materials and methods: Between 2016 and 2020, F-BT was used to treat 37 patients with low- to intermediate-risk prostate cancer. The recommended dosage was 20 Gy. Failure was defined as the existence of any prostate cancer that has persisted in-field after treatment. The F-BT oncologic and functional outcomes served as the main and secondary objectives, respectively. Results: A median 20-month follow-up (range 14–48 months). 37 patients received F-BT and enrolled in the study; no patient experienced a biochemical recurrence in the first 24 months, according to Phoenix criteria. In the control biopsies, only 6 patients showed in-field failure. The median initial IPSS was 6.5, at 6 months was 6.0, and at 24 months was 5.0. When the median ICIQ-SF score was 0 at the baseline, it remained 0 at 6-, 12-, and 24 months. Overall survival and biochemical disease-free survival after 3 years were all at 100% and 86.4%, respectively. There was no notable acute gastro-intestinal (GI) or genitourinary (GU) adverse effects. No intraoperative or perioperative complications occurred. Conclusions: For selected patients with low- or intermediate-risk localized prostate cancer, F-BT is a safe and effective therapy.Keywords
Funding Information
- Universitätsklinikum Magdeburg
This publication has 25 references indexed in Scilit:
- High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year ResultsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development StudyEuropean Urology, 2015
- High-dose-rate brachytherapy as monotherapy for prostate cancerBrachytherapy, 2014
- Comparison of Different Fractionation Schedules Toward a Single Fraction in High-Dose-Rate Brachytherapy as Monotherapy for Low-Risk Prostate Cancer Using 3-Dimensional Radiobiological ModelsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- High-Dose-Rate Interstitial Brachytherapy as Monotherapy for Clinically Localized Prostate Cancer: Treatment Evolution and Mature ResultsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Updated Results of Magnetic Resonance Imaging Guided Partial Prostate Brachytherapy for Favorable Risk Prostate Cancer: Implications for Focal TherapyJournal of Urology, 2012
- American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapyBrachytherapy, 2012
- Influence of Dose on Risk of Acute Urinary Retention After Iodine-125 Prostate BrachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Magnetic Resonance Imaging–Defined Treatment Margins in Iodine-125 Prostate BrachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Complications Following Permanent Prostate BrachytherapyEuropean Urology, 2002